Tranexamic acid (TA) is widely reported to reduce bleeding and the risk of blood transfusion in patients undergoing lower limb arthroplasty. No study in this setting has had adequate power to examine for the effect of TA on either uncommon, but clinically important, adverse events or patient-centric endpoints. A large randomised controlled trial (RCT) is required to address these questions. As a preliminary feasibility study, we conducted an investigator-initiated, prospective, randomised, double blind placebo-controlled trial in 140 patients, aged 45 years or older, undergoing elective primary or revision hip or knee joint replacement. Subjects were randomised to receive intravenous (IV) TA or a placebo. The primary endpoints were the proportion of patients receiving allogenic blood transfusion and the feasibility of extending our trial methodology to a large trial of TA in this population. Secondary endpoints included a range of adverse clinical and surgical events as well as several patient-centric questionnaires. Red blood cell transfusion occurred in 15% of all patients prior to discharge from hospital. Transfusion rates were significantly different between the TA and placebo groups (8.5% versus 21.7%, P=0.03). Three out of four feasibility endpoints were met, with recruitment being slower than expected. No significant differences were seen between groups in the secondary endpoints. Despite a lower rate of transfusion than that widely reported, IV TA reduced transfusion in patients undergoing lower limb arthroplasty. Our trial methodology would be feasible in the setting of a large multicentre study to investigate whether TA is safe and reduces bleeding in lower limb arthroplasty.
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Summary
Tranexamic acid (TA) is widely reported to reduce bleeding and the risk of blood transfusion in patients undergoing lower limb arthroplasty. No study in this setting has had adequate power to examine for the effect of TA on either uncommon, but clinically important, adverse events or patient-centric endpoints. A large randomised controlled trial (RCT) is required to address these questions. As a preliminary feasibility study, we conducted an investigator-initiated, prospective, randomised, double blind placebo-controlled trial in 140 patients, aged 45 years or older, undergoing elective primary or revision hip or knee joint replacement. Subjects were randomised to receive intravenous (IV) TA or a placebo. The primary endpoints were the proportion of patients receiving allogenic blood transfusion and the feasibility of extending our trial methodology to a large trial of TA in this population. Secondary endpoints included a range of adverse clinical and surgical events as well as several patient-centric questionnaires. Red blood cell transfusion occurred in 15% of all patients prior to discharge from hospital. Transfusion rates were significantly different between the TA and placebo groups (8.5% versus 21.7%, P=0.03). Three out of four feasibility endpoints were met, with recruitment being slower than expected. No significant differences were seen between groups in the secondary endpoints. Despite a lower rate of transfusion than that widely reported, IV TA reduced transfusion in patients undergoing lower limb arthroplasty. Our trial methodology would be feasible in the setting of a large multicentre study to investigate whether TA is safe and reduces bleeding in lower limb arthroplasty.
Key Words: arthroplasty, transfusion, feasibility, quality of life, tranexamic acid: arthroplasty Tranexamic acid (TA), a synthetic antifibrinolytic agent, has been widely reported to reduce bleeding and the risk of blood transfusion in patients undergoing lower limb arthroplasty. Furthermore, TA has been incorporated into patient blood management guidelines to reduce perioperative bleeding 1, 2 . A meta-analysis of 824 patients undergoing knee joint replacement who were randomised to intravenous (IV) TA or a placebo demonstrated significant reductions in total blood loss with TA (mean difference, 591 ml; 95% confidence intervals, CI, 536 to 647 ml, P <0.001) as well as the proportion of patients requiring blood transfusion (risk ratio, RR, 2.56; 95% CI 2.1 to 3.1) 3 . A more recent and larger meta-analysis reported on 2,594 patients undergoing knee joint replacement who had been randomised to TA or a placebo 4 . In the IV TA subgroup there was a significant reduction in transfusion rate in those who had received TA (RR, 0.35; 95% CI 0.18 to 0.67) 4 . The literature in hip joint replacement is similar. A meta-analysis of 350 patients undergoing hip joint replacement showed statistically significant but clinically modest reductions in total blood loss with IV TA (mean difference, 289 ml; 95% CI 138 to 440 ml, P <0.0002) as well as the proportion of patients requiring blood transfusion (risk difference, -0.20; 95% CI -0.29 to -0.11) 5 . Very similar reductions in bleeding and transfusion rate were reported in a more recent meta-analysis of 993 hip joint replacement patients randomised to IV TA or a placebo 6 . With the exception of a small, clinically insignificant increase in deep venous thrombosis in hip joint replacement patients 6 , no meta-analysis to date has demonstrated any increased risk of adverse events, including pulmonary embolus, with TA [3] [4] [5] [6] . More recent studies have focused on the most effective route of TA administration (i.e. IV, intraarticular and/or topical) and not considered a placebo arm necessary 7, 8 . In recent non-arthroplasty literature, several large randomised controlled trials (RCTs) (4,600 to 20,000 patients) of TA have been reported in cardiac surgery (Aspirin and TA for Coronary Artery Surgery trial 9 ), postpartum haemorrhage (WOMAN 10 ) and trauma (CRASH-2 11 ). These trials demonstrated that TA is associated with reductions in bleeding [9] [10] [11] , blood transfusion (Aspirin and TA for Coronary Artery Surgery trial 9 ), death due to bleeding (CRASH-2  11 and WOMAN   10 ) and all-cause mortality (CRASH-2
11
). Although none of these trials showed an increase in thrombotic events, the populations studied were dissimilar to those undergoing elective lower limb arthroplasty who are generally older, have comorbidities, and are not coagulopathic because of pre-existent haemorrhage or heparinisation and exposure to cardiopulmonary bypass. TA is an antifibrinolytic drug and has been associated with thrombus formation [12] [13] [14] [15] . However, the majority of RCTs of TA in the arthroplasty setting have been small, moderate quality trials primarily designed to examine bleeding endpoints. None have had sufficient power to demonstrate a difference in clinically important adverse events, particularly the recently described phenomenon of myocardial injury after non-cardiac surgery (MINS) 16 . MINS (diagnosed by a peak troponin T level of 0.03 µg/l or greater judged due to myocardial ischaemia) is a prognostically relevant myocardial injury occurring within 30 days of non-cardiac surgery 16 . The Vascular Events In Noncardiac Surgery Patients Cohort Evaluation study prospectively measured troponin T levels in 15,065 patients aged ≥45 years undergoing elective non-cardiac surgery. Thirty-day mortality was 1.9% 17 . MINS occurred in 8% of patients, accounted for the largest population-attributable risk of death, and was an independent predictor of 30-day mortality (adjusted hazard ratio, 3.87; 95% CI, 2.96 to 5.08) 16 . Thus, despite the evidence to date, in the setting of elective lower limb arthroplasty, it is possible that giving an agent such as TA to reduce bleeding may also increase the risk of thrombosis. Conversely, the POISE-2 trial, an RCT of aspirin and clonidine in 10,010 high-risk patients undergoing non-cardiac surgery, showed that an increase in bleeding perioperatively was an independent predictor of myocardial infarction. This was possibly because bleeding resulted in reduced myocardial oxygen supply 18 . By reducing bleeding, TA could theoretically reduce the risk of MINS. There was a small reduction in the incidence of myocardial infarction in the CRASH-2 trial in those that received TA 11 . Therefore, it remains unclear whether the administration of TA to reduce bleeding associated with arthroplasty surgery is associated either positively or negatively with thrombotic outcomes.
There is inconsistency in the arthroplasty literature about the size of reduction in bleeding endpoints seen with IV TA. The most recent Cochrane review reports that the IV administration of TA results in a 51% reduction in the relative risk of transfusion 19 . However, the baseline rates of transfusion in lower limb arthroplasty appear to have diminished, especially in the last five years. Alshryda et al report a 47% transfusion rate in patients receiving a placebo undergoing lower limb arthroplasty when all studies are included 20 . In those published since 2010, the incidence falls to 26%.
While outcomes such as bleeding, blood transfusion and associated adverse events are important, patient-centric endpoints such as return to function, mobilisation, quality of life and quality of recovery may be as significant to patients. A small number of RCTs of topical TA and a placebo in lower limb arthroplasty have reported functional or patient-centric endpoints three to six months postoperatively but showed no difference between groups 20 . A large randomised multicentre controlled trial of TA in lower limb arthroplasty is required to examine any association between TA administration, bleeding and adverse events as well as other patient-centric endpoints. This study has been designed primarily as a feasibility study for a large trial and to confirm recently reported transfusion rates in our clinical setting. In addition, we intended to test the feasibility of assessing patient-centric endpoints so that they may be included in any such trial.
Materials and methods
The study was conducted at two metropolitan public teaching hospitals and one private hospital in Australia. The study was a prospective, double blind, RCT of IV TA versus a placebo in 140 patients undergoing elective lower limb arthroplasty. Eligible patients were aged 45 years or older and undergoing primary or revision hip or knee joint replacement. Those with contraindications to the administration of TA including active thromboembolic disease or a history of venous (spontaneous or provoked) or arterial thromboembolic disease were excluded 21 . In addition, we excluded those with a known hypercoagulable state or severe renal impairment (estimated glomerular filtration rate <25 ml/min/1.73 m 2 ). Patients were approached in the outpatient preoperative assessment clinic and given an information sheet for consideration. They were then re-approached on admission to hospital and, if they wished to be part of the trial, consent was obtained by a medical member of the research team.
Patients were randomly assigned to receive IV TA or a placebo (normal saline) by a computer-generated randomisation sequence (random permuted blocks of four stratified by hospital, knee or hip joint replacement and primary or revision surgery) placed in consecutively numbered sealed and opaque envelopes. The study drug was prepared by an unblinded investigator, who took no further part in study procedures or patient follow-up. TA was prepared and administered per the product information-15 mg/kg at skin incision (hip joint replacement) or at tourniquet deflation (knee joint replacement) with repeat dosing at eight and 16 hours post-initial dosing. Reduced second and third doses were administered to those with renal impairment 21 . The choice of anaesthetic technique and all other aspects of perioperative management were at the discretion of the treating clinician. This included the perioperative management of antiplatelet drugs and venous thromboembolism prophylaxis. For pragmatic reasons, no red blood cell transfusion trigger was imposed, but clinicians were encouraged to adopt a haemoglobin (Hb) concentration threshold of 80 g/l before considering transfusion.
Patient baseline characteristics and perioperative data were collected. Blood was collected six to 12 hours after surgery was completed and at days one, two and three for troponin measurement. A 12-lead electrocardiogram was performed if an elevated troponin was detected. Other investigations were conducted at the discretion of the treating clinician. Hb concentration, packed cell volume (PCV) and glomerular filtration rate were recorded where performed as standard of care. Patients were visited daily while they were inpatients and contacted at three and six weeks, and three and six months to enable the administration of questionnaires and to check for the occurrence of study outcomes. A review of the patient's medical record was also conducted where required during this period.
The primary outcomes of the study were the proportion of patients receiving allogenic blood transfusion and the feasibility of extending our trial methodology to a large trial of TA and placebo in this population. A feasible trial was a priori defined as: >1 patient recruited per week per centre, >90% received two out of three doses of study drug, >90% had three out of four troponin measurements and >90% were successfully followed to six weeks. In addition, there were a number of pre-specified secondary outcomes including, the change in Hb concentration and PCV, the incidence of adverse clinical events (mortality, myocardial infarction, MINS, non-fatal cardiac arrest, transient ischaemic attack/stroke, deep venous thrombosis, pulmonary embolism, acute kidney injury, atrial fibrillation, infection/sepsis, bleeding, congestive heart failure, peripheral arterial thrombosis or coronary intervention-see
Statistical analysis
Our sample size calculation was based upon the reduction in transfusion incidence in patients who were given TA. A 2011 Cochrane review indicated a relative risk reduction of 51% for transfusion in patients undergoing hip or knee joint replacement who were given IV TA (RR 0.49, 95% CI 0.39 to 0.62) 19 . The overall transfusion incidence in patients given placebo in a 2014 meta-analysis by Alshryda et al was 47% 20 . Based on this, we calculated that a sample size of 140 would give 80% power to detect a reduction in transfusion incidence from 50% in the control group to 25% in the TA group.
The data were summarised as means with standard deviations (SD) or medians with interquartile ranges (IQR). Comparisons between treatment groups were made using the Wilcoxon rank-sum test for continuous data and Pearson's chi-square or Fisher's exact test as appropriate for dichotomous data. For outcome measures that were assessed over three or more timepoints, linear mixed-effects models were used to explore patient allocation by time interactions to determine whether trajectories over time differed between the allocation groups. The patient was treated as a random factor in each model. None of the interactions assessed were statistically significant. Hence, comparisons between groups were made separately at each timepoint. The data were analysed using SAS v9.4 (SAS Institute Inc., Cary, NC, USA). All tests were two-tailed, and significance was assessed at the 5% level. medical and perioperative characteristics at baseline are shown in Table 1 and were similar between groups.
Results

Patients
Primary outcomes
Red blood cell transfusion occurred in 15% (21/140) of patients prior to discharge from hospital. Twenty percent (15/75) of patients undergoing hip joint replacement and 9.2% (6/65) of patients undergoing knee joint replacement received a red blood cell transfusion prior to discharge. Red blood cell transfusion at any point during hospital stay occurred in six patients (8.5%) in the TA group and in 15 patients (21.7%) in the placebo group (P=0.03). Red blood cell transfusion within 24 hours of the commencement of surgery occurred in two patients (2.8%) in the TA group and in seven patients (10%) in the placebo group (P=0.09).
One hundred and forty patients were enrolled over 168 weeks of trial activity across the three sites (0.83 patients/ week/site). Of those, 137 patients (98%) received the first dose of study drug, 133 patients (95%) received at least two doses of study drug and 131 patients (93%) had at least three out of the required four troponin measurements. One hundred and thirty-nine patients (99.3%) were followed to six weeks (Table 2) .
Secondary outcomes
The fall in Hb concentration and PCV from preoperative levels to the lowest level recorded in hospital was significantly greater in patients who received the placebo compared to those who received TA. The mean difference between lowest and preoperative Hb concentration (95% CI) was 46 (43 to 50) g/l in those receiving the placebo compared with 32 (29.5 to 35.5) g/l for those receiving TA; P <0.0001. The mean difference between lowest and preoperative PCV (95% CI) was 0.14% (0.13% to 0.15%) for those receiving the placebo compared with 0.1% (0.09% to 0.11%) for those receiving TA; P <0.0001 (Figure 2 ).
There were a significantly greater number of patients who met bleeding endpoint criteria (see Appendix 1) in the placebo group (9, 13%) compared with the TA group (2, 2.8%), P=0.03. There was significantly greater observed wound ooze in those who received the placebo (23, 33%) compared with those who received TA (13, 18.3%), P=0.04. The mean (SD) length of stay was 5.7 (3.5) days. There was no difference in length of stay between study groups. There was one death in the placebo group at six weeks. There were no significant differences between groups in any other clinical secondary endpoint.
MINS occurred in seven patients in each group (9.9% TA, 10.1% placebo). One patient in each group was diagnosed with a myocardial infarction.
No significant differences were recorded between treatment groups in any of the patient-centric questionnaires (QoR-15, EQ-5D indexed, WOMAC score, Oxford Hip or Knee score) at any timepoint (Table 2, Figures 3 to 5) .
Discussion
The observed rates of transfusion in our control group were considerably lower than those in the control groups of the studies used to power this trial. Although our point estimate for reduction in transfusion rate was 60%, this represents an absolute reduction of only 13.2%, which while statistically significant, is lower than seen in older studies 6, 20 , involved only small numbers of patients and is of doubtful clinical significance. This overall lower rate of transfusion may reflect changes in patient blood management practices that have been implemented in the study hospitals over the last three to five years in line with recent recommendations 1, 2 . Of the four pre-specified feasibility outcomes, only three were met. The recruitment rate was 0.8 patients per week at each site, which was less than expected. This can largely be explained by competing research activity at each of the two main recruiting sites, which are large teaching hospitals actively involved in several concurrent large multicentre TA, tranexamic acid; SD, standard deviation; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; LMWH, low molecular weight heparin; BMI, body mass index. trials. In addition, there was a desire among the investigators that the trial be more than a single-centre study to ensure that conclusions pertaining to the success or otherwise of trial procedures could be assessed across more than one site. This had the unavoidable effect of a reduction in recruitment efficiency as other sites awaited regulatory approval.
Overall, relatively few (20%) patients who were approached to participate in the trial refused. Apart from this, trial procedure completion and patient follow-up comfortably met the feasibility targets.
There was a significant reduction in those who met the criteria for the bleeding secondary endpoint in the TA group. This indicates that although the overall difference in transfusion incidence between the groups was less than in prior studies, when bleeding did occur, it was clinically important and resulted in large reductions of Hb concentration. The observed reduction in wound ooze is consistent with the lower rates of transfusion and smaller falls in measured Hb concentration and PCV in the TA group. This is not a commonly reported endpoint, but anecdotally is a reason for delayed institution of chemical venous thromboembolism prophylaxis and delayed discharge.
The incidence of MINS in our study (10%) is consistent with the The Vascular Events In Noncardiac Surgery Patients Cohort Evaluation study 17 in which 12.1% of patients undergoing major orthopaedic surgery had a postoperative troponin ≥0.03 µg/l. In our study where troponin levels were routinely measured, and an electrocardiogram performed if elevated, myocardial infarction was diagnosed in 1.4% (2/140) patients-one in each study group. This is considerably greater than that reported in a recent large retrospective study of TA and joint replacement where myocardial infarction was reported in 0.1% of those undergoing hip or knee joint replacement 22 . This increased rate of detection highlights the fact that most postoperative myocardial ischaemia may be silent and may be missed unless troponin is routinely measured postoperatively 16 . The one death that occurred during the study period resulted from an autopsy-proven myocardial infarction at postoperative day 28 in a patient who received the placebo, bled significantly in theatre, experienced clinically important hypotension in the post-anaesthesia care unit, received four units of red blood cells in the first 24 hours postoperatively and had an asymptomatic rise in troponin at day two which did not meet the criteria for myocardial infarction (i.e. MINS).
The patient-centric questionnaires examined quite different aspects of patient experience, from quality of life to joint specific function and mobility. Consistent with previously reported studies, there was no significant difference between groups in any question at any timepoint to six months. Neither was there any significant difference in length of hospital stay. This was despite a statistically significant difference in Hb concentration and PCV, and a reduction in transfusion requirement in the TA group. If it is confirmed in future large studies that there is no functional difference between patients who do and do not receive TA, then the main difference becomes an economic one due to the decrease in use of blood products.
Our study, in showing reductions in blood transfusion with no observed increase in thrombotic complications, is consistent with published meta-analyses and systematic reviews [3] [4] [5] [6] . However, these analyses included small trials, similar to ours, which did not have adequate power to investigate the effect of TA on thrombotic events and death [3] [4] [5] [6] . The primary need now is a trial that is of sufficient size to investigate both the effectiveness and safety of TA in arthroplasty surgery. Given that we have observed an incidence of MINS in our study population, it would seem appropriate to power any larger study for a safety endpoint that includes myocardial ischaemia. In POISE-2 (aspirinplacebo) the event rate of the primary outcome (non-fatal myocardial infarction or death) in those receiving placebo was 7%. Based on this figure, any such trial of TA and placebo would require 10,000 patients (personal communication, Dr P. J. Devereaux), necessitating an international, multicentre study. Given these numbers, this would likely only be feasible in non-cardiac surgery generally as opposed to lower limb arthroplasty alone.
Our study has several weaknesses. As a small study, it did not have sufficient power to show any clinically meaningful differences between the study groups. There was no pre-specified transfusion trigger, which may have led to differences between groups based on clinical decision-making as regards transfusion at the bedside, even though the study was blinded. We elected not to assess blood loss as an outcome measure as it is notoriously difficult to measure accurately and is of questionable relevance as a stand-alone patient-centric endpoint. We also had very broad inclusion criteria, with any patient aged 45 years or older eligible to participate. This may have reduced the observed rate of medical and surgical complications. The broad inclusion criteria were chosen as this was primarily a feasibility study rather than one focused on these outcomes. Our endpoints were not independently adjudicated, and we instead relied on clinical diagnosis by the primary clinicians. This may have reduced the rate of some of the observed endpoints.
Conclusions
Transfusion incidence in lower limb arthroplasty was lower than has been previously reported. If true, this may reduce the effect of TA on transfusion incidence in future trials. Although TA leads to only modest absolute reductions in postoperative transfusion incidence, it does lead to significant reductions in the occurrence of bleeding, wound ooze and the fall of postoperative Hb concentration and PCV.
Only three of four of our feasibility targets were met with lower than expected weekly site recruitment, which may have been due to competing research activity at the sites involved. For a future study to be feasible, it will need to be conducted in the setting of a sufficiently funded, large, international, multicentre trial that will have adequate power to demonstrate that TA is at least non-inferior to placebo for thrombotic complications.
TA did not appear to affect any patient-centric endpoint, which indicates that, unless a large trial finds a difference in MINS incidence, decisions about its utility may ultimately be primarily economic from decreased use of blood products.
